Finanzen von Atossa Therapeutics Inc (ATOS)ATOSAtossa Therapeutics Inc

Evaluating the bottom line, Atossa Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -89.23%, provide a clear picture of how effectively ATOS converts its operational activities into shareholder value.

In the context of the broader market, ATOS competes directly with industry leaders such as QNRX and AYTU. With a market capitalization of $21.52M, it holds a leading position in the sector. When comparing efficiency, ATOS's gross margin of N/A stands against QNRX's N/A and AYTU's 59.90%. Such benchmarking helps identify whether Atossa Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Atossa has reported consistent losses, with a net income of -$9,589,000 in Q1 2026 and a gross profit of $0 in Q4 2024. The current ratio is 4.92, indicating sufficient short-term liquidity, but declining from previous quarters.